Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure.

Alhuraiji, Ahmad; Naqvi, Kiran; Huh, Yang O; Ho, Coty; Verstovsek, Srdan; Bose, Prithviraj.

Afiliação

Alhuraiji A; Department of Leukemia University of Texas MD Anderson Cancer Center Houston 77030 Texas.
Naqvi K; Department of Leukemia University of Texas MD Anderson Cancer Center Houston 77030 Texas.
Huh YO; Department of Hematopathology University of Texas MD Anderson Cancer Center Houston 77030 Texas.
Ho C; Oklahoma Cancer Specialists and Research Institute Tulsa 74133 Oklahoma.
Verstovsek S; Department of Leukemia University of Texas MD Anderson Cancer Center Houston 77030 Texas.
Bose P; Department of Leukemia University of Texas MD Anderson Cancer Center Houston 77030 Texas.

Clin Case Rep ; 6(1): 155-161, 2018 01.

Article em En | MEDLINE | ID: mdl-29375856

ABSTRACT

Philadelphia-negative (Ph-) myeloproliferative neoplasms (MPN) do rarely transform to acute lymphoblastic leukemia (ALL). While causality is difficult to establish, a few cases of ALL arising after exposure to lenalidomide for registered indications (multiple myeloma, myelodysplastic syndrome with 5q deletion) have been described in the literature.

Palavras-chave

Acute lymphoblastic leukemia; JAK2 V617F mutation; lenalidomide; myeloproliferative neoplasm

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article